Sterling Pharma Solutions has acquired the US arm of complex chemistry solutions provider, CiVentiChem, which is based in Cary, North Carolina, USA.
Contract development and manufacturing organization (CDMO), Sterling Pharma Solutions, has acquired the US arm of complex chemistry solutions provider, CiVentiChem, which is based in Cary, North Carolina, USA.
Through this acquisition, Sterling, a United Kingdom-based company, will be able to offer clients a local US presence while also enhancing its chemistry development capabilities to support pre-clinical and early phase clinical supply. This acquisition has been supported by GHO Capital, a new investor and major stakeholder of Sterling.
“We’re delighted to announce our acquisition of CiVentiChem in the US. We’ve been keen to expand our presence in the US market and the site’s capabilities complement our current service offering,” commented Kevin Cook, CEO of Sterling Pharma Solutions, in a press release. “The North American market now makes up 70% of our customer portfolio, which was one of the major reasons behind the decision to look for a facility in the US. This has been primarily driven by the market’s emerging pharma sector and customer demand for our specialist capabilities in complex and challenging chemistry.”
CiVentiChem will continue to operate out of its own facility in India as a separate entity to Sterling.
Source: Sterling Pharma Solutions
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.